Stanley Nattel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5060149/publications.pdf Version: 2024-02-01

		466	1091
657	65,134	130	232
papers	citations	h-index	g-index
714	714	714	27892
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2017, 14, e275-e444.	0.7	1,671
2	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.7	1,541
3	Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA). a registered branch of the European Society of	1.7	1,497
4	Cardiology (ESC) and the E. Europace, 2012, 14, 528-606. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. New England Journal of Medicine, 2008, 358, 2667-2677.	27.0	1,421
5	New ideas about atrial fibrillation 50 years on. Nature, 2002, 415, 219-226.	27.8	1,364
6	Promotion of Atrial Fibrillation by Heart Failure in Dogs. Circulation, 1999, 100, 87-95.	1.6	1,273
7	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology. 2012. 33. 171-257.	1.3	1,167
8	Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine, 2000, 342, 913-920.	27.0	1,071
9	Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 802-809.	2.8	1,044
10	The Clinical Profile and Pathophysiology of Atrial Fibrillation. Circulation Research, 2014, 114, 1453-1468.	4.5	899
11	Atrial Remodeling and Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 62-73.	4.8	897
12	lonic mechanisms underlying human atrial action potential properties: insights from a mathematical model. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H301-H321.	3.2	830
13	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, e1-e160.	1.7	767
14	Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation. Physiological Reviews, 2007, 87, 425-456.	28.8	752
15	Ionic Remodeling Underlying Action Potential Changes in a Canine Model of Atrial Fibrillation. Circulation Research, 1997, 81, 512-525.	4.5	659
16	Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure. Circulation, 2001, 104, 2608-2614.	1.6	646
17	Atrial Fibrillation Pathophysiology. Circulation, 2011, 124, 2264-2274.	1.6	646
18	Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty. New England Journal of Medicine, 1997, 337, 365-372.	27.0	578

#	Article	IF	CITATIONS
19	Role of the Autonomic Nervous System in Atrial Fibrillation. Circulation Research, 2014, 114, 1500-1515.	4.5	578
20	Atrial Remodeling and Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 2335-2345.	2.8	544
21	Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression. Circulation Research, 2014, 114, 1483-1499.	4.5	530
22	Enhanced Sarcoplasmic Reticulum Ca ²⁺ Leak and Increased Na ⁺ -Ca ²⁺ Exchanger Function Underlie Delayed Afterdepolarizations in Patients With Chronic Atrial Fibrillation. Circulation, 2012, 125, 2059-2070.	1.6	523
23	Recent advances in the molecular pathophysiology of atrial fibrillation. Journal of Clinical Investigation, 2011, 121, 2955-2968.	8.2	480
24	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace, 2016, 18, 1455-1490.	1.7	471
25	Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. Canadian Journal of Cardiology, 2012, 28, 125-136.	1.7	461
26	Modifiable Risk Factors and Atrial Fibrillation. Circulation, 2017, 136, 583-596.	1.6	451
27	Prevention of Atrial Fibrillation. Circulation, 2009, 119, 606-618.	1.6	446
28	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm, 2017, 14, e3-e40.	0.7	442
29	Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. Journal of Physiology, 2007, 582, 675-693.	2.9	434
30	Evidence for Two Components of Delayed Rectifier K ⁺ Current in Human Ventricular Myocytes. Circulation Research, 1996, 78, 689-696.	4.5	409
31	Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training. Circulation, 2011, 123, 13-22.	1.6	394
32	Cellular and Molecular Mechanisms of Atrial Arrhythmogenesis in Patients With Paroxysmal Atrial Fibrillation. Circulation, 2014, 129, 145-156.	1.6	386
33	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2014, 30, 1114-1130.	1.7	382
34	Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation, 2018, 138, 2227-2242.	1.6	376
35	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace, 2018, 20, 157-208.	1.7	375
36	Differential Distribution of Cardiac Ion Channel Expression as a Basis for Regional Specialization in Electrical Function. Circulation Research, 2002, 90, 939-950.	4.5	366

#	Article	IF	CITATIONS
37	Effects of Experimental Heart Failure on Atrial Cellular and Ionic Electrophysiology. Circulation, 2000, 101, 2631-2638.	1.6	356
38	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Journal of Arrhythmia, 2017, 33, 369-409.	1.2	348
39	Role of Inflammation in Atrial Fibrillation Pathophysiology and Management. Circulation Journal, 2015, 79, 495-502.	1.6	345
40	Molecular Mechanisms Underlying Ionic Remodeling in a Dog Model of Atrial Fibrillation. Circulation Research, 1999, 84, 776-784.	4.5	328
41	Functional Mechanisms Underlying Tachycardia-Induced Sustained Atrial Fibrillation in a Chronic Dog Model. Circulation, 1997, 96, 4027-4035.	1.6	326
42	Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovascular Research, 2011, 89, 744-753.	3.8	325
43	Importance of Refractoriness Heterogeneity in the Enhanced Vulnerability to Atrial Fibrillation Induction Caused by Tachycardia-Induced Atrial Electrical Remodeling. Circulation, 1998, 98, 2202-2209.	1.6	324
44	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	1.7	313
45	Intra-Atrial Pressure Increases Rate and Organization of Waves Emanating From the Superior Pulmonary Veins During Atrial Fibrillation. Circulation, 2003, 108, 668-671.	1.6	311
46	Postoperative atrial fibrillation: mechanisms, manifestations and management. Nature Reviews Cardiology, 2019, 16, 417-436.	13.7	296
47	Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. European Heart Journal, 2006, 27, 512-518.	2.2	290
48	Molecular and Cellular Mechanisms of AtrialÂFibrosis in AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2017, 3, 425-435.	3.2	290
49	New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet, The, 2010, 375, 1212-1223.	13.7	261
50	Antisense Oligodeoxynucleotides Directed Against Kv1.5 mRNA Specifically Inhibit Ultrarapid Delayed Rectifier K ⁺ Current in Cultured Adult Human Atrial Myocytes. Circulation Research, 1997, 80, 572-579.	4.5	257
51	lonic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovascular Research, 1999, 42, 477-489.	3.8	256
52	Atrial Fibrillation Promotion by Endurance Exercise. Journal of the American College of Cardiology, 2013, 62, 68-77.	2.8	252
53	Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment. JAMA Cardiology, 2018, 3, 532.	6.1	252
54	Characterization of a transient outward K ⁺ current with inward rectification in canine ventricular myocytes. American Journal of Physiology - Cell Physiology, 1998, 274, C577-C585.	4.6	251

#	Article	IF	CITATIONS
55	Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs. Circulation, 2004, 110, 2313-2319.	1.6	249
56	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	1.7	243
57	Calcium-Handling Abnormalities Underlying Atrial Arrhythmogenesis and Contractile Dysfunction in Dogs With Congestive Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 93-102.	4.8	239
58	Cholinergic Atrial Fibrillation in a Computer Model of a Two-Dimensional Sheet of Canine Atrial Cells With Realistic Ionic Properties. Circulation Research, 2002, 90, E73-87.	4.5	237
59	Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovascular Research, 2004, 63, 236-244.	3.8	237
60	Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm, 2009, 6, 1802-1809.	0.7	237
61	Atrial Ischemia Promotes Atrial Fibrillation in Dogs. Circulation, 2003, 107, 1930-1936.	1.6	233
62	lonic Determinants of Functional Reentry in a 2-D Model of Human Atrial Cells During Simulated Chronic Atrial Fibrillation. Biophysical Journal, 2005, 88, 3806-3821.	0.5	232
63	MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. Journal of Clinical Investigation, 2013, 123, 1939-1951.	8.2	232
64	Differential Behaviors of Atrial Versus Ventricular Fibroblasts. Circulation, 2008, 117, 1630-1641.	1.6	231
65	Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovascular Research, 2003, 60, 315-325.	3.8	230
66	Transient Receptor Potential Canonical-3 Channel–Dependent Fibroblast Regulation in Atrial Fibrillation. Circulation, 2012, 126, 2051-2064.	1.6	228
67	Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs. Circulation, 2002, 105, 2672-2678.	1.6	226
68	Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. Journal of Physiology, 2003, 551, 801-813.	2.9	224
69	Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. American Journal of Cardiology, 1999, 84, 11-19.	1.6	222
70	MicroRNA29. Circulation, 2013, 127, 1466-1475.	1.6	222
71	Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy. Circulation Research, 2020, 127, 51-72.	4.5	222
72	Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1031-H1041.	3.2	219

#	Article	IF	CITATIONS
73	Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovascular Research, 1994, 28, 1540-1546.	3.8	218
74	Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation. Circulation, 2005, 112, 471-481.	1.6	215
75	Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovascular Research, 2002, 54, 456-461.	3.8	214
76	Mechanisms of Atrial Fibrillation: Lessons From Animal Models. Progress in Cardiovascular Diseases, 2005, 48, 9-28.	3.1	213
77	Tachycardia-Induced Changes in Na ⁺ Current in a Chronic Dog Model of Atrial Fibrillation. Circulation Research, 1997, 81, 1045-1052.	4.5	209
78	Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovascular Research, 1998, 38, 441-450.	3.8	206
79	Left-to-Right Atrial Inward Rectifier Potassium Current Gradients in Patients With Paroxysmal Versus Chronic Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 472-480.	4.8	204
80	Differential Distribution of Inward Rectifier Potassium Channel Transcripts in Human Atrium Versus Ventricle. Circulation, 1998, 98, 2422-2428.	1.6	199
81	Cellular Mechanisms of Atrial Contractile Dysfunction Caused by Sustained Atrial Tachycardia. Circulation, 1998, 98, 719-727.	1.6	197
82	Pulmonary Vein Region Ablation in Experimental Vagal Atrial Fibrillation. Circulation, 2008, 117, 470-477.	1.6	196
83	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2018, 34, 1371-1392.	1.7	195
84	Potential Molecular Basis of Different Physiological Properties of the Transient Outward K ⁺ Current in Rabbit and Human Atrial Myocytes. Circulation Research, 1999, 84, 551-561.	4.5	193
85	Early management of atrial fibrillation to prevent cardiovascular complications. European Heart Journal, 2014, 35, 1448-1456.	2.2	190
86	Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet, The, 2015, 386, 672-679.	13.7	188
87	Ionic Mechanisms of Regional Action Potential Heterogeneity in the Canine Right Atrium. Circulation Research, 1998, 83, 541-551.	4.5	186
88	Atrial fibrillation. Nature Reviews Disease Primers, 2016, 2, 16016.	30.5	185
89	Mechanisms by Which Adenosine Restores Conduction in Dormant Canine Pulmonary Veins. Circulation, 2010, 121, 963-972.	1.6	183
90	Atrial Fibrillation and Congestive Heart Failure: Specific Considerations at the Intersection of Two Common and Important Cardiac Disease Sets. Journal of Cardiovascular Electrophysiology, 2002, 13, 399-405.	1.7	182

#	Article	IF	CITATIONS
91	Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovascular Research, 2006, 69, 798-807.	3.8	181
92	The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. European Heart Journal, 2012, 33, 1870-1877.	2.2	181
93	Changes in Connexin Expression and the Atrial Fibrillation Substrate in Congestive Heart Failure. Circulation Research, 2009, 105, 1213-1222.	4.5	178
94	Lone Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 1715-1723.	2.8	177
95	Kir3-Based Inward Rectifier Potassium Current. Circulation, 2006, 113, 1730-1737.	1.6	176
96	Innovative approaches to anti-arrhythmic drug therapy. Nature Reviews Drug Discovery, 2006, 5, 1034-1049.	46.4	175
97	Cellular Signaling Underlying Atrial Tachycardia Remodeling of L-type Calcium Current. Circulation Research, 2008, 103, 845-854.	4.5	174
98	Potential Ionic Mechanism for Repolarization Differences Between Canine Right and Left Atrium. Circulation Research, 2001, 88, 1168-1175.	4.5	173
99	A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. Journal of Physiology, 2002, 540, 15-27.	2.9	173
100	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference â€research perspectives in AF'. European Heart Journal, 2009, 30, 2969-2980.	2.2	173
101	Dissociation Between Ionic Remodeling and Ability to Sustain Atrial Fibrillation During Recovery From Experimental Congestive Heart Failure. Circulation, 2004, 109, 412-418.	1.6	172
102	Atrial Fibrillation Promotion With Long-Term Repetitive Obstructive Sleep Apnea in a Rat Model. Journal of the American College of Cardiology, 2014, 64, 2013-2023.	2.8	172
103	HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Research, 2002, 62, 4843-8.	0.9	172
104	Novel molecular targets for atrial fibrillation therapy. Nature Reviews Drug Discovery, 2012, 11, 275-291.	46.4	170
105	Controversies in atrial fibrillation. Lancet, The, 2006, 367, 262-272.	13.7	169
106	The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovascular Research, 2016, 109, 467-479.	3.8	166
107	Atrial Cardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 756-765.	2.8	166
108	Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study. Journal of Nuclear Cardiology, 1995, 2, 3-17.	2.1	164

#	Article	IF	CITATIONS
109	Basic Mechanisms of Atrial Fibrillation—Very New Insights into Very Old Ideas. Annual Review of Physiology, 2000, 62, 51-77.	13.1	164
110	Role for MicroRNA-21 in Atrial Profibrillatory Fibrotic Remodeling Associated With Experimental Postinfarction Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1027-1035.	4.8	161
111	Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. Journal of Molecular and Cellular Cardiology, 2010, 49, 639-646.	1.9	160
112	Ryanodine Receptor–Mediated Calcium Leak Drives Progressive Development of an Atrial Fibrillation Substrate in a Transgenic Mouse Model. Circulation, 2014, 129, 1276-1285.	1.6	160
113	Induction of Heat Shock Response Protects the Heart Against Atrial Fibrillation. Circulation Research, 2006, 99, 1394-1402.	4.5	158
114	Molecular basis of funny current (If) in normal and failing human heart. Journal of Molecular and Cellular Cardiology, 2008, 45, 289-299.	1.9	158
115	Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium. Circulation, 2003, 107, 1440-1446.	1.6	157
116	Role of Small-Conductance Calcium-Activated Potassium Channels in Atrial Electrophysiology and Fibrillation in the Dog. Circulation, 2014, 129, 430-440.	1.6	153
117	Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation. Circulation Research, 2020, 127, 1036-1055.	4.5	152
118	Ionic Remodeling in the Heart. Circulation Research, 2000, 87, 440-447.	4.5	151
119	Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model. Cardiovascular Research, 2005, 66, 472-481.	3.8	151
120	Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes and Development, 2006, 20, 2355-2360.	5.9	151
121	Mechanisms of Atrial Tachyarrhythmias Associated With Coronary Artery Occlusion in a Chronic Canine Model. Circulation, 2011, 123, 137-146.	1.6	151
122	The T-Type Ca 2+ Channel Blocker Mibefradil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs. Circulation, 1999, 100, 2191-2197.	1.6	148
123	Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failureâ~†. Cardiovascular Research, 2007, 74, 75-84.	3.8	144
124	Pulmonary vein isolation using "contact force―ablation: The effect on dormant conduction and long-term freedom from recurrent atrial fibrillation—A prospective study. Heart Rhythm, 2014, 11, 1919-1924.	0.7	144
125	Characterization of a hyperpolarizationâ€activated timeâ€dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. Journal of Physiology, 2004, 557, 583-597.	2.9	142
126	Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. Journal of Physiology, 2004, 561, 735-748.	2.9	141

#	Article	IF	CITATIONS
127	Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. Journal of Molecular and Cellular Cardiology, 2007, 43, 223-229.	1.9	141
128	Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation. Cardiovascular Research, 1999, 42, 298-308.	3.8	138
129	Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1767-H1785.	3.2	138
130	Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: A novel consideration in atrial remodelingâ~†. Cardiovascular Research, 2007, 76, 442-452.	3.8	136
131	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm, 2017, 14, e445-e494.	0.7	135
132	Effects of Probucol on Vascular Remodeling After Coronary Angioplasty. Circulation, 1999, 99, 30-35.	1.6	134
133	Protein Kinase C Activates ATP-Sensitive K + Current in Human and Rabbit Ventricular Myocytes. Circulation Research, 1996, 78, 492-498.	4.5	134
134	Potassium Channel Subunit Remodeling in Rabbits Exposed to Long-Term Bradycardia or Tachycardia. Circulation, 2006, 113, 345-355.	1.6	133
135	Animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace, 2010, 12, 160-172.	1.7	131
136	Translational Challenges in Atrial Fibrillation. Circulation Research, 2018, 122, 752-773.	4.5	131
137	Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling. Circulation, 2007, 116, 2101-2109.	1.6	130
138	Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 55, 1796-1802.	2.8	129
139	Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nature Reviews Cardiology, 2016, 13, 575-590.	13.7	128
140	Model-Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. Circulation, 2007, 115, 310-318.	1.6	127
141	Mechanisms of Atrial Fibrillation Termination by Pure Sodium Channel Blockade in an Ionically-Realistic Mathematical Model. Circulation Research, 2005, 96, e35-47.	4.5	126
142	Cardiac Ultrarapid Delayed Rectifiers. Cellular Physiology and Biochemistry, 1999, 9, 217-226.	1.6	125
143	Impairment of HERG K+ Channel Function by Tumor Necrosis Factor-α. Journal of Biological Chemistry, 2004, 279, 13289-13292.	3.4	125
144	Funny Current Downregulation and Sinus Node Dysfunction Associated With Atrial Tachyarrhythmia. Circulation, 2009, 119, 1576-1585.	1.6	123

#	Article	IF	CITATIONS
145	lonic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. Journal of Physiology, 2013, 591, 4189-4206.	2.9	122
146	Role of the Wntâ€Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. Journal of Physiology, 2013, 591, 1409-1432.	2.9	120
147	Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovascular Research, 2001, 49, 751-761.	3.8	119
148	Activation of Histone Deacetylase-6 Induces Contractile Dysfunction Through Derailment of α-Tubulin Proteostasis in Experimental and Human Atrial Fibrillation. Circulation, 2014, 129, 346-358.	1.6	118
149	MicroRNA Regulation and Cardiac Calcium Signaling. Circulation Research, 2014, 114, 689-705.	4.5	117
150	MicroRNAs and atrial fibrillation: mechanisms and translational potential. Nature Reviews Cardiology, 2015, 12, 80-90.	13.7	116
151	G protein oupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. Journal of Physiology, 2012, 590, 1313-1330.	2.9	115
152	Phosphodiesterase-2 Is Up-Regulated in Human Failing Hearts and Blunts Î ² -Adrenergic Responses in Cardiomyocytes. Journal of the American College of Cardiology, 2013, 62, 1596-1606.	2.8	115
153	Adrenergic Modulation of Ultrarapid Delayed Rectifier K + Current in Human Atrial Myocytes. Circulation Research, 1996, 78, 903-915.	4.5	113
154	Ionic current abnormalities associated with prolonged action potentials in cardiomyocytes from diseased human right ventricles. Heart Rhythm, 2004, 1, 460-468.	0.7	112
155	Multiple Potential Molecular Contributors to Atrial Hypocontractility Caused by Atrial Tachycardia Remodeling in Dogs. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 530-541.	4.8	112
156	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Canadian Journal of Cardiology, 2011, 27, 47-59.	1.7	112
157	Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. American Journal of Medicine, 1990, 89, 235-238.	1.5	111
158	Comparison of Ion-Channel Subunit Expression in Canine Cardiac Purkinje Fibers and Ventricular Muscle. Circulation Research, 2002, 91, 790-797.	4.5	110
159	Sex Differences in Cardiac Electrophysiology and Clinical Arrhythmias: Epidemiology, Therapeutics, and Mechanisms. Canadian Journal of Cardiology, 2014, 30, 783-792.	1.7	109
160	Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	109
161	Molecular basis of species-specific expression of repolarizing K ⁺ currents in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1641-H1649.	3.2	107
162	Mechanisms of Ischemic Preconditioning in Rat Hearts. Circulation, 1995, 92, 2259-2265.	1.6	107

#	Article	IF	CITATIONS
163	Expression of Multiple Subtypes of Muscarinic Receptors and Cellular Distribution in the Human Heart. Molecular Pharmacology, 2001, 59, 1029-1036.	2.3	106
164	Atrial Ionic Remodeling Induced by Atrial Tachycardia in the Presence of Congestive Heart Failure. Circulation, 2004, 110, 1520-1526.	1.6	106
165	Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm, 2012, 9, 1409-1416.e1.	0.7	106
166	Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm, 2008, 5, 451-459.	0.7	104
167	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace, 2009, 11, 860-885.	1.7	104
168	Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation. Circulation, 2000, 102, 104-112.	1.6	103
169	Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1002-H1012.	3.2	103
170	Nicotine Is a Potent Blocker of the Cardiac A-Type K ⁺ Channels. Circulation, 2000, 102, 1165-1171.	1.6	102
171	Barium block of Kir2 and human cardiac inward rectifier currents: evidence for subunit-heteromeric contribution to native currents. Cardiovascular Research, 2003, 59, 328-338.	3.8	102
172	Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovascular Research, 2001, 52, 217-225.	3.8	101
173	The effect of vagally induced dispersion of action potential duration on atrial arrhythmogenesis. Heart Rhythm, 2004, 1, 334-344.	0.7	101
174	Calcium Handling Abnormalities in Atrial Fibrillation as a Target for Innovative Therapeutics. Journal of Cardiovascular Pharmacology, 2008, 52, 293-299.	1.9	100
175	Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects. British Journal of Pharmacology, 2004, 142, 1300-1308.	5.4	97
176	Nuclear-delimited Angiotensin Receptor-mediated Signaling Regulates Cardiomyocyte Gene Expression. Journal of Biological Chemistry, 2010, 285, 22338-22349.	3.4	97
177	Atrial Fibrillation: Basic Mechanisms, Remodeling and Triggers. Journal of Interventional Cardiac Electrophysiology, 2005, 13, 181-193.	1.3	96
178	Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovascular Research, 2006, 69, 865-875.	3.8	96
179	Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2009, 46, 385-394.	1.9	96
180	Ionic Remodeling of Cardiac Purkinje Cells by Congestive Heart Failure. Circulation, 2001, 104, 2095-2100.	1.6	95

#	Article	IF	CITATIONS
181	Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization. Cardiovascular Research, 2005, 67, 520-528.	3.8	95
182	Role of autonomic nervous system in atrial fibrillation. International Journal of Cardiology, 2019, 287, 181-188.	1.7	95
183	Contrasting Gene Expression Profiles in Two Canine Models of Atrial Fibrillation. Circulation Research, 2007, 100, 425-433.	4.5	94
184	Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovascular Research, 2001, 49, 762-770.	3.8	93
185	Differential Protein Kinase C Isoform Regulation and Increased Constitutive Activity of Acetylcholine-Regulated Potassium Channels in Atrial Remodeling. Circulation Research, 2011, 109, 1031-1043.	4.5	93
186	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. Journal of Arrhythmia, 2016, 32, 247-278.	1.2	92
187	Changes in IK,ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovascular Research, 2007, 77, 35-43.	3.8	91
188	The Molecular and Ionic Specificity of Antiarrhythmic Drug Actions. Journal of Cardiovascular Electrophysiology, 1999, 10, 272-282.	1.7	90
189	Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?. Cardiovascular Research, 2002, 54, 347-360.	3.8	90
190	Differential distribution of Kir2.1 and Kir2.3 subunits in canine atrium and ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1123-H1133.	3.2	90
191	Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovascular Research, 2008, 81, 491-499.	3.8	90
192	Clinical and Mechanistic Issues in Early Repolarization. Journal of the American College of Cardiology, 2010, 56, 1177-1186.	2.8	89
193	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Canadian Journal of Cardiology, 2017, 33, 965-976.	1.7	89
194	Comparison of ion channel distribution and expression in cardiomyocytes of canine pulmonary veins versus left atrium. Cardiovascular Research, 2005, 65, 104-116.	3.8	88
195	Feedback Remodeling of Cardiac Potassium Current Expression. Circulation, 2008, 118, 983-992.	1.6	88
196	Newer developments in the management of atrial fibrillation. American Heart Journal, 1995, 130, 1094-1106.	2.7	87
197	Atrial Tachycardia Remodeling of Pulmonary Vein Cardiomyocytes. Circulation, 2005, 111, 728-735.	1.6	87
198	Endoplasmic Reticulum Stress Is Associated With Autophagy and Cardiomyocyte Remodeling in Experimental and Human Atrial Fibrillation. Journal of the American Heart Association, 2017, 6, .	3.7	87

#	Article	IF	CITATIONS
199	Cellular electrophysiology of atrial fibrillation. Cardiovascular Research, 2002, 54, 259-269.	3.8	86
200	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovascular Research, 2011, 92, 67-74.	3.8	84
201	The role of cellular senescence in cardiac disease: basic biology and clinical relevance. Nature Reviews Cardiology, 2022, 19, 250-264.	13.7	84
202	The Treatment of Atrial Fibrillation. Drugs, 1994, 48, 345-371.	10.9	83
203	Pulmonary vein reentry—Properties and size matter: Insights from a computational analysis. Heart Rhythm, 2007, 4, 1553-1562.	0.7	83
204	Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. Journal of Molecular and Cellular Cardiology, 2010, 49, 851-863.	1.9	83
205	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 1-55.	1.3	83
206	Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. Journal of Physiology, 2007, 582, 1205-1217.	2.9	81
207	Mechanisms of atrial remodeling and clinical relevance. Current Opinion in Cardiology, 2005, 20, 21-5.	1.8	81
208	Atrial-Selective Approaches for the Treatment of Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 787-792.	2.8	80
209	Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 2014, 64, 823-831.	2.8	79
210	Fibroblast Inward-Rectifier Potassium Current Upregulation in Profibrillatory Atrial Remodeling. Circulation Research, 2015, 116, 836-845.	4.5	79
211	α-Adrenergic Control of Volume-Regulated Cl â^ Currents in Rabbit Atrial Myocytes. Circulation Research, 1995, 77, 379-393.	4.5	79
212	Multivariate clinical models and quantitative dipyridamole-thallium imaging to predict cardiac morbidity and death after vascular reconstruction. Journal of Vascular Surgery, 1991, 14, 160-169.	1.1	77
213	Antiarrhythmic Drug Classifications. Drugs, 1991, 41, 672-701.	10.9	77
214	Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovascular Research, 1998, 37, 627-635.	3.8	77
215	Oxidative Preconditioning and Apoptosis in L-cells. Journal of Biological Chemistry, 2001, 276, 26357-26364.	3.4	77
216	Unique Cardiac Purkinje Fiber Transient Outward Current Î ² -Subunit Composition. Circulation Research, 2013, 112, 1310-1322.	4.5	77

#	Article	IF	CITATIONS
217	Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation. Frontiers in Physiology, 2018, 9, 1383.	2.8	77
218	Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2008, 45, 685-693.	1.9	76
219	Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation,Âand Oxidative Stress. Journal of the American College of Cardiology, 2014, 64, 1441-1448.	2.8	76
220	Controversies About Atrial Fibrillation Mechanisms. Circulation Research, 2017, 120, 1396-1398.	4.5	76
221	Atrial cell action potential parameter fitting using genetic algorithms. Medical and Biological Engineering and Computing, 2005, 43, 561-571.	2.8	75
222	Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): Standardised reporting for model reproducibility, interoperability, and data sharing. Progress in Biophysics and Molecular Biology, 2011, 107, 4-10.	2.9	75
223	Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling. Journal of the American College of Cardiology, 2015, 66, 47-58.	2.8	75
224	Method for Simultaneous Epicardial and Endocardial Mapping of In Vivo Canine Heart: Application to Atrial Conduction Properties and Arrhythmia Mechanisms. Journal of Cardiovascular Electrophysiology, 2001, 12, 548-555.	1.7	74
225	Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovascular Research, 2002, 54, 438-446.	3.8	74
226	Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. American Journal of Cardiology, 1980, 45, 627-632.	1.6	73
227	Transmembranel Ca contributes to rate-dependent changes of action potentials in human ventricular myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H98-H106.	3.2	73
228	Consequences of Atrial Tachycardia-Induced Remodeling Depend on the Preexisting Atrial Substrate. Circulation, 2002, 105, 251-257.	1.6	73
229	Mechanisms Underlying Rate-Dependent Remodeling of Transient Outward Potassium Current in Canine Ventricular Myocytes. Circulation Research, 2008, 103, 733-742.	4.5	73
230	Demystifying rotors and their place in clinical translation of atrial fibrillation mechanisms. Nature Reviews Cardiology, 2017, 14, 509-520.	13.7	72
231	Right Atrial Mechanisms of AtrialÂFibrillation in a Rat Model of RightÂHeartÂDisease. Journal of the American College of Cardiology, 2019, 74, 1332-1347.	2.8	72
232	Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. Journal of Molecular and Cellular Cardiology, 2006, 40, 173-184.	1.9	71
233	Sex-based transmural differences in cardiac repolarization and ionic-current properties in canine left ventricles. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H570-H580.	3.2	69
234	Novel Approaches for Pharmacological Management of Atrial Fibrillation. Drugs, 2009, 69, 757-774.	10.9	69

#	Article	IF	CITATIONS
235	Connexins and Atrial Fibrillation. Circulation, 2012, 125, 203-206.	1.6	69
236	KvLQT1 Modulates the Distribution and Biophysical Properties of HERG. Journal of Biological Chemistry, 2004, 279, 1233-1241.	3.4	67
237	Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovascular Research, 1998, 37, 567-577.	3.8	65
238	Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H1075-H1080.	3.2	65
239	New Approaches to Atrial Fibrillation Management. Drugs, 2002, 62, 2377-2397.	10.9	65
240	Post-transcriptional alterations in the expression of cardiac Na+ channel subunits in chronic heart failure. Journal of Molecular and Cellular Cardiology, 2004, 37, 91-100.	1.9	65
241	Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice. Drugs, 2010, 70, 573-603.	10.9	65
242	Evidence That Outwardly Rectifying Cl â^' Channels Underlie Volume-Regulated Cl â^' Currents in Heart. Circulation Research, 1997, 80, 103-113.	4.5	65
243	Time-dependent transients in an ionically based mathematical model of the canine atrial action potential. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H1437-H1451.	3.2	64
244	Mechanisms of atrial fibrillation termination by rapidly unbinding Na ⁺ channel blockers: insights from mathematical models and experimental correlates. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1489-H1504.	3.2	63
245	Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: A comparative multicenter study. Heart Rhythm, 2012, 9, 1025-1030.	0.7	63
246	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation. JACC: Clinical Electrophysiology, 2015, 1, 105-115.	3.2	63
247	Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovascular Research, 2008, 78, 63-70.	3.8	62
248	Transforming growth factor-β and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. Cardiovascular Research, 2011, 91, 62-70.	3.8	62
249	Late pulmonary vein reconnection: insights into mechanisms of atrial fibrillation recurrence after pulmonary vein isolation. Europace, 2013, 15, 1143-1143.	1.7	61
250	Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Archiv European Journal of Physiology, 2002, 443, 520-531.	2.8	58
251	Properties, Expression and Potential Roles of Cardiac K + Channel Accessory Subunits: MinK, MiRPs, KChIP, and KChAP. Journal of Membrane Biology, 2003, 194, 141-152.	2.1	58
252	Functional expression of Kir2.x in human aortic endothelial cells: the dominant role of Kir2.2. American Journal of Physiology - Cell Physiology, 2005, 289, C1134-C1144.	4.6	58

#	Article	IF	CITATIONS
253	The Calcium/Calmodulin/Kinase System and Arrhythmogenic Afterdepolarizations in Bradycardia-Related Acquired Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 295-304.	4.8	58
254	The role of pulmonary veins vs. autonomic ganglia in different experimental substrates of canine atrial fibrillation. Cardiovascular Research, 2011, 89, 825-833.	3.8	58
255	Basic Electrophysiology of the Pulmonary Veins and Their Role in Atrial Fibrillation:. Precipitators, Perpetuators, and Perplexers. Journal of Cardiovascular Electrophysiology, 2003, 14, 1372-1375.	1.7	57
256	Canine Ventricular KCNE2 Expression Resides Predominantly in Purkinje Fibers. Circulation Research, 2003, 93, 189-191.	4.5	57
257	Atrial Structural Remodeling as an Antiarrhythmic Target. Journal of Cardiovascular Pharmacology, 2008, 52, 4-10.	1.9	57
258	Ca ²⁺ -Related Signaling and Protein Phosphorylation Abnormalities Play Central Roles in a New Experimental Model of Electrical Storm. Circulation, 2011, 123, 2192-2203.	1.6	57
259	Region-specific gene expression profiles in the left atria of patients with valvular atrial fibrillation. Heart Rhythm, 2013, 10, 383-391.	0.7	57
260	Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. Nature, 2020, 587, 460-465.	27.8	55
261	Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1717-H1725.	3.2	54
262	Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE): Methods and Rationale. Canadian Journal of Cardiology, 2012, 28, 184-190.	1.7	54
263	Computational models of atrial cellular electrophysiology and calcium handling, and their role in atrial fibrillation. Journal of Physiology, 2016, 594, 537-553.	2.9	54
264	Relative Role of Alkalosis and Sodium Ions in Reversal of Class I Antiarrhythmic Drug–Induced Sodium Channel Blockade by Sodium Bicarbonate. Circulation, 1996, 94, 1954-1961.	1.6	54
265	Idiopathic atrial fibrillation in dogs: Electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide. Journal of the American College of Cardiology, 1995, 26, 277-286.	2.8	53
266	Normal function of HERG K+channels expressed in HEK293 cells requires basal protein kinase B activity. FEBS Letters, 2003, 534, 125-132.	2.8	53
267	Atrial Electrophysiology and Mechanisms of Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, S5-S11.	2.0	52
268	Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: A clinical-experimental correlation. Heart Rhythm, 2011, 8, 1426-1433.	0.7	52
269	JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. Cardiovascular Research, 2017, 113, 310-320.	3.8	52
270	Dysfunction of Myosin Lightâ€Chain 4 (MYL4) Leads to Heritable Atrial Cardiomyopathy With Electrical, Contractile, and Structural Components: Evidence From Geneticallyâ€Engineered Rats. Journal of the American Heart Association, 2017, 6, .	3.7	52

#	Article	IF	CITATIONS
271	Insights into Mechanisms of Antiarrhythmic Drug Action From Experimental Models of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 1997, 8, 469-480.	1.7	51
272	Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology. Cardiac Electrophysiology Clinics, 2021, 13, 25-35.	1.7	51
273	Ionic Determinants of Atrial Fibrillation and Ca2+Channel Abnormalities. Circulation Research, 1999, 85, 473-476.	4.5	50
274	Coronary artery endothelial protection after local delivery of 17β-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. Journal of the American College of Cardiology, 2001, 38, 1570-1576.	2.8	50
275	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm, 2010, 7, 1862-1869.	0.7	50
276	Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. European Heart Journal, 2016, 37, 640-650.	2.2	50
277	Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovascular Research, 2008, 78, 422-428.	3.8	49
278	Ion Channel Subunit Expression Changes in Cardiac Purkinje Fibers. Circulation Research, 2009, 104, 1113-1122.	4.5	49
279	From Guidelines to Bench: Implications of Unresolved Clinical Issues for Basic Investigations of Atrial Fibrillation Mechanisms. Canadian Journal of Cardiology, 2011, 27, 19-26.	1.7	49
280	Role of K _{ATP} Channels in the Maintenance of Ventricular Fibrillation in Cardiomyopathic Human Hearts. Circulation Research, 2011, 109, 1309-1318.	4.5	49
281	Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovascular Research, 2008, 79, 61-69.	3.8	48
282	Metabolic Considerations in Atrial Fibrillation ― Mechanistic Insights and Therapeutic Opportunities ―. Circulation Journal, 2017, 81, 1749-1757.	1.6	48
283	Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. Canadian Journal of Cardiology, 2021, 37, 1607-1618.	1.7	48
284	Dihydropyridine and beta adrenergic receptor binding in dogs with tachycardia-induced atrial fibrillation. Cardiovascular Research, 1999, 42, 434-442.	3.8	47
285	Tissueâ€specific expression of two human Ca _v 1.2 isoforms under the control of distinct 5′ flanking regulatory elements. FEBS Letters, 2003, 546, 349-354.	2.8	47
286	Transcriptional profiling of ion channel genes in Brugada syndrome and other right ventricular arrhythmogenic diseases. European Heart Journal, 2009, 30, 487-496.	2.2	47
287	A proposal for new clinical concepts in the management of atrial fibrillation. American Heart Journal, 2012, 164, 292-302.e1.	2.7	47
288	Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model. PLoS ONE, 2013, 8, e55427.	2.5	47

#	Article	IF	CITATIONS
289	Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. Journal of Molecular and Cellular Cardiology, 2014, 77, 113-124.	1.9	47
290	Computational models of atrial fibrillation: achievements, challenges, and perspectives for improving clinical care. Cardiovascular Research, 2021, 117, 1682-1699.	3.8	47
291	Kir2.4 and Kir2.1 K+channel subunits coâ€assemble: a potential new contributor to inward rectifier current heterogeneity. Journal of Physiology, 2002, 544, 337-349.	2.9	46
292	Pulmonary Vein Isolation Using a Pace-Capture–Guided Versus an Adenosine-Guided Approach. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1103-1108.	4.8	46
293	Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. European Heart Journal, 2021, 42, 532-540.	2.2	46
294	Therapeutic Blood Lidocaine Concentrations after Local Anesthesia for Cardiac Electrophysiologic Studies. New England Journal of Medicine, 1979, 301, 418-420.	27.0	45
295	Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. Journal of the American College of Cardiology, 1989, 13, 1190-1194.	2.8	45
296	Differential Alterations of Receptor Densities of Three Muscarinic Acetylcholine Receptor Subtypes and Current Densities of the Corre-sponding K ⁺ Channels in Canine Atria with Atrial Fibrillation Induced by Experimental Congestive Heart Failure. Cellular Physiology and Biochemistry, 2004, 14, 31-40.	1.6	45
297	The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy. Cardiovascular Research, 2007, 74, 104-113.	3.8	45
298	Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors. Journal of Molecular and Cellular Cardiology, 2013, 62, 58-68.	1.9	45
299	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovascular Research, 2022, 118, 2415-2427.	3.8	45
300	Effects of sustained Î ² -adrenergic stimulation on ionic currents of cultured adult guinea pig cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H880-H889.	3.2	44
301	Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block. Europace, 2007, 9, 869-874.	1.7	44
302	Effects of Resveratrol (<i>trans</i> -3,5,4′-Trihydroxystilbene) Treatment on Cardiac Remodeling following Myocardial Infarction. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 916-923.	2.5	44
303	Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Current Opinion in Cardiology, 2009, 24, 50-55.	1.8	44
304	Exchange Protein Directly Activated by cAMP Mediates Slow Delayed-Rectifier Current Remodeling by Sustained β-Adrenergic Activation in Guinea Pig Hearts. Circulation Research, 2014, 114, 993-1003.	4.5	44
305	Recent Advances in Understanding the Pharmacology of Amiodarone. Drugs, 1988, 36, 121-131.	10.9	43
306	Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog. Journal of Cardiovascular Pharmacology, 2006, 47, 123-132.	1.9	43

#	Article	IF	CITATIONS
307	Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca2+ in adult cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2013, 62, 189-202.	1.9	43
308	The 2014 Atrial Fibrillation Guidelines Companion: AÂPractical Approach to the Use of the Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2015, 31, 1207-1218.	1.7	43
309	Intracellular Angiotensinâ€II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion. Journal of the American Heart Association, 2017, 6, .	3.7	43
310	Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Mediates the Differential Responsiveness of Atrial Versus Ventricular Fibroblasts to Transforming Growth Factor-β. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 790-798.	4.8	42
311	Potassium Channel Blockade Enhances Atrial Fibrillation–Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade. Circulation, 2015, 132, 2203-2211.	1.6	41
312	Relationship Between an Arrhythmogenic Action of Lidocaine and Its Effects on Excitation Patterns in Acutely Ischemic Porcine Myocardium. Journal of Cardiovascular Pharmacology, 1986, 8, 126-136.	1.9	40
313	The Pharmacokinetics of Lignocaine and β-Adrenoceptor Antagonists in Patients with Acute Myocardial Infarction. Clinical Pharmacokinetics, 1987, 13, 293-316.	3.5	40
314	Electrophysiologic Remodeling: Journal of Cardiovascular Electrophysiology, 1999, 10, 1553-1556.	1.7	39
315	Predicting the entrainment of reentrant cardiac waves using phase resetting curves. Physical Review E, 2002, 65, 021908.	2.1	39
316	Comparison of Ca2+-handling properties of canine pulmonary vein and left atrial cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2290-H2300.	3.2	39
317	Atrial fibrillation: evidence for genetically determined disease. Current Opinion in Cardiology, 2008, 23, 176-183.	1.8	39
318	Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle. Circulation, 2009, 119, 1824-1831.	1.6	39
319	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. Journal of the American Heart Association, 2014, 3, .	3.7	39
320	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. Journal of Cardiovascular Electrophysiology, 1992, 3, 266-280.	1.7	38
321	A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H466-H474.	3.2	38
322	Remodeling of Ca2+-handling by atrial tachycardia: evidence for a role in loss of rate-adaptation. Cardiovascular Research, 2002, 54, 416-426.	3.8	38
323	AMP-Activated Protein Kinase. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 860-867.	4.8	38
324	A Clinical Approach to Early Repolarization. Circulation, 2013, 127, 1620-1629.	1.6	38

#	Article	IF	CITATIONS
325	Fibroblast Electrical Remodeling in Heart Failure and Potential Effects on Atrial Fibrillation. Biophysical Journal, 2014, 107, 2444-2455.	0.5	38
326	A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominantâ€negative mutation of the <i>KCNE1</i> gene. British Journal of Pharmacology, 2016, 173, 2046-2061.	5.4	38
327	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. Cardiovascular Research, 2021, 117, 1776-1789.	3.8	38
328	Long-term risk stratification with dipyridamole imaging. American Heart Journal, 1995, 129, 880-886.	2.7	37
329	Dose-Dependence of 4-Aminopyridine Plasma Concentrations and Electrophysiological Effects in Dogs. Circulation, 2000, 101, 1179-1184.	1.6	37
330	Properties of potassium currents in Purkinje cells of failing human hearts. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H2495-H2503.	3.2	37
331	The pathology of atrial fibrillation in dogs. Journal of Veterinary Cardiology, 2005, 7, 121-129.	0.9	37
332	Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs. Circulation, 1995, 92, 1300-1311.	1.6	37
333	Inflammasome Signaling in AtrialÂFibrillation. Journal of the American College of Cardiology, 2022, 79, 2349-2366.	2.8	37
334	Comparative mechanisms of action of antiarrhythmic drugs. American Journal of Cardiology, 1993, 72, F13-F17.	1.6	36
335	A Mathematical Model of Human Atrioventricular Nodal Function Incorporating Concealed Conduction. Bulletin of Mathematical Biology, 2002, 64, 1083-1099.	1.9	36
336	Age as a Critical Determinant of Atrial Fibrillation: A Two-sided Relationship. Canadian Journal of Cardiology, 2018, 34, 1396-1406.	1.7	36
337	Pharmacological Prevention of Atrial Tachycardia Induced Atrial Remodeling as a Potential Therapeutic Strategy. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 752-764.	1.2	35
338	Paroxysmal Atrial Fibrillation and Pulmonary Veins: Relationships Between Clinical Forms and Automatic Versus Re-entrant Mechanisms. Canadian Journal of Cardiology, 2013, 29, 1147-1149.	1.7	35
339	Renewal Theory as a Universal Quantitative Framework to Characterize Phase Singularity Regeneration in Mammalian Cardiac Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007569.	4.8	35
340	Pilot Study and Protocol of the Canadian Trial of Atrial Fibrillation (CTAF). American Journal of Cardiology, 1997, 80, 464-468.	1.6	34
341	Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes. Cardiovascular Research, 1998, 38, 395-404.	3.8	34
342	Marked differences between atrial and ventricular gene-expression remodeling in dogs with experimental heart failure. Journal of Molecular and Cellular Cardiology, 2008, 45, 821-831.	1.9	34

#	Article	IF	CITATIONS
343	Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: Evidence for clinically significant IKr-IKs α-subunit interaction. Heart Rhythm, 2009, 6, 1792-1801.	0.7	34
344	Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw. Canadian Journal of Cardiology, 2017, 33, 283-286.	1.7	34
345	Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling. Cardiovascular Research, 2019, 115, 94-106.	3.8	34
346	Effects of taurine depletion on rat cardiac electrophysiology: and studies. Life Sciences, 1987, 40, 1017-1026.	4.3	33
347	Dynamic Behavior of the Atrioventricular Node: Journal of Cardiovascular Electrophysiology, 1994, 5, 90-102.	1.7	33
348	Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. Journal of Physiology, 1999, 516, 385-398.	2.9	33
349	Phospholipid Metabolite 1-Palmitoyl-Lysophosphatidylcholine Enhances Human Ether-a-Go-Go -Related Gene (HERG) K + Channel Function. Circulation, 2001, 104, 2645-2648.	1.6	33
350	Ion-channel mRNA-expression profiling: Insights into cardiac remodeling and arrhythmic substrates. Journal of Molecular and Cellular Cardiology, 2010, 48, 96-105.	1.9	33
351	Management of Atrial Fibrillation in the Year 2033: NewÂConcepts, Tools, and Applications Leading to Personalized Medicine. Canadian Journal of Cardiology, 2013, 29, 1141-1146.	1.7	33
352	Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. Cardiovascular Research, 2001, 50, 85-96.	3.8	32
353	Development of a computer algorithm for the detection of phase singularities and initial application to analyze simulations of atrial fibrillation. Chaos, 2002, 12, 764-778.	2.5	32
354	Mechanisms of Termination of Atrial Fibrillation by Class I Antiarrhythmic Drugs:. Journal of Cardiovascular Electrophysiology, 2003, 14, S133-S139.	1.7	32
355	Electrical storm: recent pathophysiological insights and therapeutic consequences. Basic Research in Cardiology, 2013, 108, 336.	5.9	32
356	Congestive Heart Failure Effects on Atrial Fibroblast Phenotype: Differences between Freshly-Isolated and Cultured Cells. PLoS ONE, 2012, 7, e52032.	2.5	32
357	Age-dependent lidocaine disposition in patients with acute myocardial infarction. Clinical Pharmacology and Therapeutics, 1985, 37, 381-386.	4.7	31
358	Molecular evidence for a role of Shaw (Kv3) potassium channel subunits in potassium currents of dog atrium. Journal of Physiology, 2000, 527, 467-478.	2.9	31
359	Arrhythmogenic Ionic Remodeling Adaptive Responses with Maladaptive Consequences. Trends in Cardiovascular Medicine, 2001, 11, 295-301.	4.9	31
360	Adrenergic control of a constitutively active acetylcholine-regulated potassium current in canine atrial cardiomyocytes. Cardiovascular Research, 2007, 74, 406-415.	3.8	31

#	Article	lF	CITATIONS
361	New Directions in Cardiac Arrhythmia Management: Present Challenges and Future Solutions. Canadian Journal of Cardiology, 2014, 30, S420-S430.	1.7	31
362	How does fibrosis promote atrial fibrillation persistence: <i>in silico</i> findings, clinical observations, and experimental data. Cardiovascular Research, 2016, 110, 295-297.	3.8	31
363	Association of Atrial Fibrillation Episode Duration With Arrhythmia Recurrence Following Ablation. JAMA Network Open, 2020, 3, e208748.	5.9	31
364	Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it. Cardiovascular Research, 2021, 117, 1616-1631.	3.8	31
365	Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. European Heart Journal, 2002, 23, 1050-1056.	2.2	30
366	In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovascular Research, 2004, 61, 705-714.	3.8	30
367	Calciumâ€activated potassium current: a novel ion channel candidate in atrial fibrillation. Journal of Physiology, 2009, 587, 1385-1386.	2.9	30
368	Atrial Fibrillation Compendium. Circulation Research, 2014, 114, 1447-1452.	4.5	30
369	Electrical coupling between cardiomyocytes and fibroblasts: experimental testing of a challenging and important concept. Cardiovascular Research, 2018, 114, 349-352.	3.8	30
370	Mechanisms and Clinical Significance of Arrhythmia-Induced Cardiomyopathy. Canadian Journal of Cardiology, 2018, 34, 1449-1460.	1.7	30
371	Role of the lysyl oxidase enzyme family in cardiac function and disease. Cardiovascular Research, 2019, 115, 1820-1837.	3.8	30
372	Model systems for the discovery and development of antiarrhythmic drugs. Progress in Biophysics and Molecular Biology, 2008, 98, 328-339.	2.9	29
373	Roles of the Left Atrial Roof and Pulmonary Veins in the Anatomic Substrate for Persistent Atrial Fibrillation and Ablation in a Canine Model. Journal of the American College of Cardiology, 2010, 56, 1728-1736.	2.8	29
374	A high-fat diet increases risk of ventricular arrhythmia in female rats: enhanced arrhythmic risk in the absence of obesity or hyperlipidemia. Journal of Applied Physiology, 2010, 108, 933-940.	2.5	28
375	Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation–remodeled hearts. JCI Insight, 2020, 5, .	5.0	28
376	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Canadian Journal of Cardiology, 2019, 35, 1069-1077.	1.7	27
377	Effects of flecainide on the rate dependence of atrial refractoriness, atrial repolarization and atrioventricular node conduction in anesthetized dogs. Journal of the American College of Cardiology, 1992, 19, 1335-1342.	2.8	26
378	Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. Cardiovascular Research, 2000, 46, 151-161.	3.8	26

#	Article	IF	CITATIONS
379	Potential mechanisms for the enhancement of HERG K+ channel function by phospholipid metabolites. British Journal of Pharmacology, 2004, 141, 586-599.	5.4	26
380	Single-channel recordings of a rapid delayed rectifier current in adult mouse ventricular myocytes: basic properties and effects of divalent cations. Journal of Physiology, 2004, 556, 401-413.	2.9	26
381	Effects of the Diuretic Agent Indapamide on Na + , Transient Outward, and Delayed Rectifier Currents in Canine Atrial Myocytes. Circulation Research, 1998, 83, 158-166.	4.5	25
382	Identification of atrial tissue in pulmonary veins using intravascular ultrasound. Journal of the American Society of Echocardiography, 2003, 16, 982-987.	2.8	25
383	Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm, 2009, 6, 1465-1472.	0.7	25
384	New insights into the molecular basis of atrial fibrillation: mechanistic and therapeutic implications. Cardiovascular Research, 2011, 89, 689-691.	3.8	25
385	Calcium handling and atrial fibrillation. Wiener Medizinische Wochenschrift, 2012, 162, 287-291.	1.1	25
386	In Silico Optimization of Atrial Fibrillation-Selective Sodium Channel Blocker Pharmacodynamics. Biophysical Journal, 2012, 102, 951-960.	0.5	25
387	Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: Potential significance in arrhythmogenesis and antiarrhythmic therapy. Heart Rhythm, 2014, 11, 2092-2100.	0.7	25
388	Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. British Journal of Pharmacology, 2003, 138, 1475-1484.	5.4	24
389	Rate-dependence of atrial tachycardia effects on atrial refractoriness and atrial fibrillation maintenance. Cardiovascular Research, 2009, 81, 90-97.	3.8	24
390	New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation. Cardiovascular Research, 2021, 117, 1645-1661.	3.8	24
391	Optimal Management with Class I and Class III Antiarrhythmic Drugs Should Be Done in the Outpatient Setting Journal of Cardiovascular Electrophysiology, 1999, 10, 472-481.	1.7	23
392	Spotlight on atrial fibrillation—the 'complete arrhythmia'. Cardiovascular Research, 2002, 54, 197-203.	3.8	23
393	Atrial Infarction-Induced Spontaneous Focal Discharges and Atrial Fibrillation in Sheep. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005659.	4.8	23
394	Does gut microbiota affect atrial rhythm? Causalities and speculations. European Heart Journal, 2021, 42, 3521-3525.	2.2	23
395	Is There a Future for Antiarrhythmic Drug Therapy?. Drugs, 1998, 56, 767-781.	10.9	22
396	The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. Cardiovascular Research, 2001, 50, 75-84.	3.8	22

#	Article	IF	CITATIONS
397	Resolving the M-cell debate: Why and how. Heart Rhythm, 2011, 8, 1293-1295.	0.7	22
398	Adenosine Testing in Atrial Flutter Ablation: Unmasking of Dormant Conduction Across the Cavotricuspid Isthmus and Risk of Recurrence. Journal of Cardiovascular Electrophysiology, 2013, 24, 995-1001.	1.7	22
399	Electrophysiological mechanisms by which hypothyroidism delays repolarization in guinea pig hearts. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H211-H220.	3.2	21
400	Local delivery of 17β-estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model. Thrombosis and Haemostasis, 2005, 94, 1042-1047.	3.4	21
401	Wave block formation in homogeneous excitable media following premature excitations: Dependence on restitution relations. Physical Review E, 2005, 72, 031919.	2.1	21
402	Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management. Current Vascular Pharmacology, 2007, 5, 185-194.	1.7	21
403	Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovascular Research, 2011, 91, 420-428.	3.8	21
404	Interactions between cardiac fibrosis spatial pattern and ionic remodeling on electrical wave propagation. , 2011, 2011, 4669-72.		21
405	Regional Ion Channel Gene Expression Heterogeneity and Ventricular Fibrillation Dynamics in Human Hearts. PLoS ONE, 2014, 9, e82179.	2.5	21
406	Loss of Cardiomyocyte Integrin-Linked Kinase Produces an Arrhythmogenic Cardiomyopathy in Mice. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 921-932.	4.8	21
407	Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. Europace, 2019, 21, 1261-1269.	1.7	21
408	Sleep Apnea and Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 87-94.	1.7	21
409	Prognostic significance of ventricular arrhythmias post-myocardial infarction. Canadian Journal of Cardiology, 2003, 19, 1393-404.	1.7	21
410	Stateâ€dependent barium block of wildâ€ŧype and inactivationâ€deficient HERG channels in Xenopus oocytes. Journal of Physiology, 2000, 526, 265-278.	2.9	20
411	Defining "Culprit Mechanisms―in Arrhythmogenic Cardiac Remodeling. Circulation Research, 2004, 94, 1403-1405.	4.5	20
412	C-terminal Domain of Kv4.2 and Associated KChIP2 Interactions Regulate Functional Expression and Gating of Kv4.2. Journal of Biological Chemistry, 2006, 281, 27134-27144.	3.4	20
413	Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF). Canadian Journal of Cardiology, 2008, 24, 709-713.	1.7	20
414	Dronedarone in Atrial Fibrillation — Jekyll and Hyde?. New England Journal of Medicine, 2011, 365, 2321-2322.	27.0	20

#	Article	IF	CITATIONS
415	Close connections between contraction and rhythm: a new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us. European Heart Journal, 2017, 38, 35-37.	2.2	20
416	Inositol Trisphosphate Receptors and Nuclear Calcium in Atrial Fibrillation. Circulation Research, 2021, 128, 619-635.	4.5	20
417	Differential Interactions of Na+ Channel Toxins with T-type Ca2+ Channels. Journal of General Physiology, 2008, 132, 101-113.	1.9	19
418	T-Type Calcium Current Contributes to Escape Automaticity and Governs the Occurrence of Lethal Arrhythmias After Atrioventricular Block in Mice. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 799-808.	4.8	19
419	Nestin is a Marker of Lung Remodeling Secondary to Myocardial Infarction and Type I Diabetes in the Rat. Journal of Cellular Physiology, 2015, 230, 170-179.	4.1	19
420	Atrial Fibrillation and Body Composition. Journal of the American College of Cardiology, 2017, 69, 2498-2501.	2.8	19
421	Biomarkers in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 221-233.	1.7	19
422	What is an antiarrhythmic drug? From clinical trials to fundamental concepts. American Journal of Cardiology, 1990, 66, 96-99.	1.6	18
423	Demonstration of an Inward Na+-Ca2+ Exchange Current in Adult Human Atrial Myocytes. Annals of the New York Academy of Sciences, 1996, 779, 525-528.	3.8	18
424	Randomized Trial Comparing Intravenous Nitroglycerin and Heparin for Treatment of Unstable Angina Secondary to Restenosis After Coronary Artery Angioplasty. Circulation, 2000, 101, 955-961.	1.6	18
425	A Single Residue in the S6 Transmembrane Domain Governs the Differential Flecainide Sensitivity of Voltage-Gated Potassium Channels. Molecular Pharmacology, 2005, 68, 305-316.	2.3	18
426	Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs. Heart Rhythm, 2005, 2, S180.	0.7	18
427	Atrial Fibrillation-Associated Remodeling Does Not Promote Atrial Thrombus Formation in Canine Models. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1168-1175.	4.8	18
428	Atrial Repolarization Alternans as a Path to Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2012, 23, 1013-1015.	1.7	18
429	Rate-Dependent Role of I Kur in Human Atrial Repolarization and Atrial Fibrillation Maintenance. Biophysical Journal, 2017, 112, 1997-2010.	0.5	18
430	Comparison of Atrial Remodeling Caused by Sustained Atrial Flutter Versus Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 76, 374-388.	2.8	18
431	The effects of cardiac stretch on atrial fibroblasts: analysis of the evidence and potential role in atrial fibrillation. Cardiovascular Research, 2022, 118, 440-460.	3.8	18
432	Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation. Circulation Research, 2021, 129, 804-820.	4.5	18

#	Article	IF	CITATIONS
433	Pharmacologic Response of Cesium-Induced Ventricular Tachyarrhythmias in Anesthetized Dogs. Journal of Cardiovascular Pharmacology, 1990, 15, 552-561.	1.9	17
434	Acquired delayed rectifier channelopathies: how heart disease and antiarrhythmic drugs mimic potentially-lethal congenital cardiac disorders. Cardiovascular Research, 2000, 48, 188-190.	3.8	17
435	Properties of a Time-Dependent Potassium Current in Pig Atrium: Evidence for a Role of Kv1.5 in Repolarization. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 898-906.	2.5	17
436	Atrial tachycardia induces remodelling of muscarinic receptors and their coupled potassium currents in canine left atrial and pulmonary vein cardiomyocytes. British Journal of Pharmacology, 2007, 152, 1021-1032.	5.4	17
437	Association of neonatal hypoxia with lasting changes in left ventricular gene expression: An animal model. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 538-546.e1.	0.8	17
438	Voltage-Clamp-Based Methods for the Detection of Constitutively Active Acetylcholine-Gated IK,ACh Channels in the Diseased Heart. Methods in Enzymology, 2010, 484, 653-675.	1.0	17
439	CrossTalk proposal: Prolonged intense exercise training does lead to myocardial damage. Journal of Physiology, 2013, 591, 4939-4941.	2.9	17
440	Disease and region-related cardiac fibroblast potassium current variations and potential functional significance. Cardiovascular Research, 2014, 102, 487-496.	3.8	17
441	Wavelet analysis of cardiac optical mapping data. Computers in Biology and Medicine, 2015, 65, 243-255.	7.0	17
442	Attenuation of Class 3 and Sinus Node Effects of Amiodarone by Experimental Hypothyroidism. Journal of Cardiovascular Pharmacology, 1989, 13, 447-450.	1.9	16
443	Electrophysiological Effects of alpha-Adrenergic Stimulation. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 578-582.	1.2	16
444	Impact of tissue geometry on simulated cholinergic atrial fibrillation: A modeling study. Chaos, 2011, 21, 013108.	2.5	16
445	Corticosteroid use during pulmonary vein isolation is associated with a higher prevalence of dormant pulmonary vein conduction. Heart Rhythm, 2013, 10, 1569-1575.	0.7	16
446	Photoreleasable ligands to study intracrine angiotensin II signalling. Journal of Physiology, 2015, 593, 521-539.	2.9	16
447	A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. Canadian Journal of Cardiology, 2017, 33, 1577-1586.	1.7	16
448	Calciumâ€dependent potassium channels control proliferation of cardiac progenitor cells and bone marrowâ€derived mesenchymal stem cells. Journal of Physiology, 2018, 596, 2359-2379.	2.9	16
449	Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling. Cardiovascular Research, 2021, 117, 462-471.	3.8	16
450	The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy. Journal of Cardiovascular Pharmacology, 2015, 66, 432-440.	1.9	15

#	Article	IF	CITATIONS
451	Caged ligands to study the role of intracellular GPCRs. Methods, 2016, 92, 72-77.	3.8	15
452	Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance. Cardiovascular Research, 2023, 119, 614-630.	3.8	15
453	An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. Cardiovascular Research, 2019, 115, 1975-1985.	3.8	14
454	Pulmonary Vein Stenosis After Atrial Fibrillation Ablation: Insights From the ADVICE Trial. Canadian Journal of Cardiology, 2020, 36, 1965-1974.	1.7	14
455	M/M/Infinity Birth-Death Processes – A Quantitative Representational Framework to Summarize and Explain Phase Singularity and Wavelet Dynamics in Atrial Fibrillation. Frontiers in Physiology, 2020, 11, 616866.	2.8	14
456	Recent Insights Into Mechanisms and Clinical Approaches to Electrical Storm. Canadian Journal of Cardiology, 2022, 38, 439-453.	1.7	14
457	P3-17. Heart Rhythm, 2006, 3, S183.	0.7	13
458	Inappropriate sinus tachycardia and beta-receptor autoantibodies: A mechanistic breakthrough?. Heart Rhythm, 2006, 3, 1187-1188.	0.7	13
459	Hypoxia in early life is associated with lasting changes in left ventricular structure and function at maturity in the rat. International Journal of Cardiology, 2012, 156, 165-173.	1.7	13
460	Dronedarone. Cardiac Electrophysiology Clinics, 2016, 8, 453-465.	1.7	13
461	MicroRNA-135a regulates sodium–calcium exchanger gene expression and cardiac electrical activity. Heart Rhythm, 2017, 14, 739-748.	0.7	13
462	Proarrhythmic Atrial Calcium Cycling in the Diseased Heart. Advances in Experimental Medicine and Biology, 2012, 740, 1175-1191.	1.6	13
463	New insights into the mechanisms and management of atrial fibrillation. Cmaj, 2002, 167, 1012-20.	2.0	13
464	Cardiac pathways distinguish two epistatic modules enacting BP quantitative trait loci and candidate gene analysis. Hypertension Research, 2009, 32, 631-637.	2.7	12
465	Anthrax Lethal Factor Activates K+ Channels To Induce IL-1Î ² Secretion in Macrophages. Journal of Immunology, 2011, 186, 5236-5243.	0.8	12
466	Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes. American Journal of Physiology - Renal Physiology, 2013, 304, F849-F862.	2.7	12
467	Linking cellular energy state to atrial fibrillation pathogenesis: Potential role of adenosine monophosphate–activated protein kinase. Heart Rhythm, 2020, 17, 1398-1404.	0.7	12
468	Postoperative Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 123-132.	1.7	12

#	Article	IF	CITATIONS
469	Aldosterone antagonism and atrial fibrillation: time for clinical assessment?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2005, 26, 2079-2080.	2.2	11
470	Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: A new unifying concept with basic and clinical relevance. Heart Rhythm, 2005, 2, 632-633.	0.7	11
471	Characterization of the cardiac KCNE1 gene promoter. Cardiovascular Research, 2007, 73, 82-91.	3.8	11
472	Pharmacological elimination of motion artifacts during optical imaging of cardiac tissues: Is blebbistatin the answer?. Heart Rhythm, 2007, 4, 627-628.	0.7	11
473	Exercise training as a treatment for heart failure: potential mechanisms and clinical implications. Journal of Physiology, 2009, 587, 5011-5013.	2.9	11
474	Ventricular Proarrhythmic Effects of Atrial Fibrillation are Modulated by Depolarization and Repolarization Anomalies in Patients with Left Ventricular Dysfunction. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 99-105.	1.2	11
475	Canadian Journal of Cardiology January 2013: Genetics and More. Canadian Journal of Cardiology, 2013, 29, 1-2.	1.7	11
476	Changes in the Atrial Transcriptome and Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 5-7.	4.8	11
477	Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 411-431.	4.5	11
478	Effects of Ionic Remodeling on Cardiac Antiarrhythmic Drug Actions. Journal of Cardiovascular Pharmacology, 2001, 38, 809-811.	1.9	11
479	Binge Alcohol Exposure Triggers Atrial Fibrillation Through T-Type Ca ²⁺ Channel Upregulation via Protein Kinase C (PKC) / Glycogen Synthesis Kinase 3Î ² (GSK3Î ²) / Nuclear Factor of Activated T-Cells (NFAT) Signalingā€€â€• An Experimental Account of Holiday Heart Syndrome ―. Circulation Journal, 2020, 84, 1931-1940.	1.6	11
480	Effects of Heart Disease on Cardiac Ion Current Density Versus Current Amplitude. Circulation Research, 2008, 102, 1298-1300.	4.5	10
481	Sudden Cardio Arrest: When normal ECG variants turn lethal. Nature Medicine, 2010, 16, 646-647.	30.7	10
482	Role of constitutively active acetylcholine-mediated potassium current in atrial contractile dysfunction caused by atrial tachycardia remodelling. Europace, 2010, 12, 1490-1497.	1.7	10
483	Canadian Journal of Cardiology in 2014: From Percutaneous Intervention to Regenerative Medicine. Canadian Journal of Cardiology, 2014, 30, 1-2.	1.7	10
484	Physical activity and atrial fibrillation risk: it's complicated; and sex is critical. European Heart Journal, 2020, 41, 1487-1489.	2.2	10
485	Atrial-Specific LKB1 Knockdown Represents a Novel Mouse Model of Atrial Cardiomyopathy With Spontaneous Atrial Fibrillation. Circulation, 2021, 144, 909-912.	1.6	10
486	Ultrarapid Delayed Rectifier K ⁺ Current in H9c2 Rat Ventricular Cell Line: Biophysical Property and Molecular Identity. Cellular Physiology and Biochemistry, 2002, 12, 215-226.	1.6	9

#	Article	IF	CITATIONS
487	Lost anchors cost lives. Nature, 2003, 421, 587-589.	27.8	9
488	Age, gender, and supraventricular arrhythmias: Roles of ion channels, connexins, and tissue architecture?. Heart Rhythm, 2004, 1, 397-398.	0.7	9
489	Novel Targets for Cardiac Antiarrhythmic Drug Development. Current Pharmaceutical Design, 2005, 11, 1959-1974.	1.9	9
490	Distinct genomic replacements from Lewis correct diastolic dysfunction, attenuate hypertension, and reduce left ventricular hypertrophy in Dahl salt-sensitive rats. Journal of Hypertension, 2008, 26, 1935-1943.	0.5	9
491	Calcium-dependent potassium channels in the heart: clarity and confusion. Cardiovascular Research, 2014, 101, 185-186.	3.8	9
492	The pioneering work of George Mines on cardiac arrhythmias: groundbreaking ideas that remain influential in contemporary cardiac electrophysiology. Journal of Physiology, 2016, 594, 2377-2386.	2.9	9
493	Cycle Length Alternation During Supraventricular Tachycardia: Occurrence and Mechanism in a Canine Model of AV Reentrant Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 314-325.	1.2	8
494	Antiarrhythmic Prophylaxis after Acute Myocardial Infarction. Drugs, 1993, 45, 9-14.	10.9	8
495	The Kv4.2 N-terminal restores fast inactivation and confers KChIP2 modulatory effects on N-terminal-deleted Kv1.4 channels. Pflugers Archiv European Journal of Physiology, 2004, 449, 235-47.	2.8	8
496	Cellular properties of C-terminal KCNH2 long QT syndrome mutations: Description and divergence from clinical phenotypes. Heart Rhythm, 2008, 5, 1159-1167.	0.7	8
497	Triggering of cardiac arrhythmic events in long QT syndrome: lessons from funny bunnies. Journal of Physiology, 2012, 590, 1311-1312.	2.9	8
498	Atrial Tachycardia, Flutter, and Fibrillation. , 2005, , 283-363.		8
499	Arrhythmogenic right ventricular dysplasia type 1 and mutations in transforming growth factor ?3 gene regulatory regions: a breakthrough?. Cardiovascular Research, 2005, 65, 302-304.	3.8	7
500	Delayedâ€rectifier potassium currents and the control of cardiac repolarization: Noble and Tsien 40 years after. Journal of Physiology, 2008, 586, 5849-5852.	2.9	7
501	G-protein signaling and arrhythmogenic atrial remodeling: Relevance to novel therapeutic targets in atrial fibrillation. Heart Rhythm, 2009, 6, 85-86.	0.7	7
502	Physiological <i>versus</i> pathological cardiac electrical remodelling: potential basis and relevance to clinical management. Journal of Physiology, 2010, 588, 4855-4856.	2.9	7
503	F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 667-677.	3.0	7
504	Deciphering the fundamental mechanisms of atrial fibrillation: a quest for over a century. Cardiovascular Research, 2016, 109, 465-466.	3.8	7

#	Article	IF	CITATIONS
505	Characterization of Sgo1 expression in developing and adult mouse. Gene Expression Patterns, 2017, 25-26, 36-45.	0.8	7
506	Aging and Protein Kinase Activation. Circulation Research, 2018, 122, 799-801.	4.5	7
507	Taking the Pulse of Atrial Fibrillation: A Practical Approach to Rate Control. Canadian Journal of Cardiology, 2018, 34, 1526-1530.	1.7	7
508	The Inability of the Choroid to Revascularize in Oxygen-Induced Retinopathy Results from Increased p53/miR-Let-7b Activity. American Journal of Pathology, 2019, 189, 2340-2356.	3.8	7
509	Prevalence and clinical impact of spontaneous and adenosine-induced pulmonary vein reconduction in the Contact-Force vs. Cryoballoon Atrial Fibrillation Ablation (CIRCA-DOSE) study. Heart Rhythm, 2020, 17, 897-904.	0.7	7
510	One Ring to Rule Them All: Continuous Monitoring of Patients With Secondary Atrial Fibrillation Points to a Unifying Underlying Mechanism. Canadian Journal of Cardiology, 2021, 37, 686-689.	1.7	7
511	Cohesin-protein Shugoshin-1 controls cardiac automaticity via HCN4 pacemaker channel. Nature Communications, 2021, 12, 2551.	12.8	7
512	Driver Regions in Atrial Fibrillation Associated with Congestive Heart Failure: Where Are They, and What Are They Telling Us?. Journal of Cardiovascular Electrophysiology, 2005, 16, 050928083434001.	1.7	6
513	Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: Evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy. Journal of Molecular and Cellular Cardiology, 2008, 45, 707-708.	1.9	6
514	Advances in drug, ablation, and device therapy for cardiac arrhythmias. Nature Reviews Cardiology, 2016, 13, 67-68.	13.7	6
515	Aortic Vascular Calcification: Cholesterol Lowering Does Not Reduce Progression in Patients With Familial Hypercholesterolemia—or Does It?. Canadian Journal of Cardiology, 2017, 33, 594-596.	1.7	6
516	The Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: A Look Back Over the Last 10 Years and a Look Forward. Canadian Journal of Cardiology, 2020, 36, 1839-1842.	1.7	6
517	Electrophysiological Effects of Atrial Epicardial Adipose Tissue. Journal of the American College of Cardiology, 2020, 76, 1212-1214.	2.8	6
518	Transcriptomic Profiling of Canine Atrial Fibrillation Models After One Week of Sustained Arrhythmia. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009887.	4.8	6
519	Rotors anchored by refractory islands drive torsades de pointes in an experimental model of electrical storm. Heart Rhythm, 2022, 19, 318-329.	0.7	6
520	Use of Excessive Lidocaine Concentrations for Local Anesthesia. New England Journal of Medicine, 1980, 302, 122-122.	27.0	5
521	Determinants and significance of diltiazem plasma concentrations after acute myocardial infarction. American Journal of Cardiology, 1990, 66, 1422-1428.	1.6	5
522	Absence of pharmacokinetic interaction between amiodarone and lidocaine. American Journal of Cardiology, 1994, 73, 92-94.	1.6	5

#	Article	IF	CITATIONS
523	A spotlight on electrophysiological remodeling and the molecular biology of ion channels. Cardiovascular Research, 1999, 42, 267-269.	3.8	5
524	The clinical relevance of connexin gating: how to control communication in the heart. Heart Rhythm, 2004, 1, 234.	0.7	5
525	Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 332-333.	3.3	5
526	Controversies in cardiology – Authors' reply. Lancet, The, 2006, 367, 1315-1316.	13.7	5
527	Case Studies with the Experts: Management Decisions in Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, S1-12; quiz S13-5.	1.7	5
528	Exercise training, inflammation and heart failure: working out to cool down. Journal of Physiology, 2010, 588, 2525-2526.	2.9	5
529	Therapy with omega-3 fatty acids—is the case closed?. Nature Reviews Cardiology, 2011, 8, 126-128.	13.7	5
530	Adenosine and Atrial Arrhythmias: Exploring Electrophysiological Mechanisms <i>In Vivo</i> . PACE - Pacing and Clinical Electrophysiology, 2012, 35, 553-555.	1.2	5
531	Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application. Expert Review of Cardiovascular Therapy, 2015, 13, 769-782.	1.5	5
532	Targeting MicroRNA-208a to Suppress Adverse Postmyocardial Infarction Remodelling Related to RNA Activation of Endoglin Gene Expression. Canadian Journal of Cardiology, 2015, 31, 591-592.	1.7	5
533	An Emerging Malignant Arrhythmia Epidemic Due to Loperamide Abuse. JACC: Clinical Electrophysiology, 2016, 2, 790-792.	3.2	5
534	Potassium Channel Remodeling in Heart Disease. Cardiac Electrophysiology Clinics, 2016, 8, 337-347.	1.7	5
535	Dataset of Sgo1 expression in cardiac, gastrointestinal, hepatic and neuronal tissue in mouse. Data in Brief, 2017, 13, 731-737.	1.0	5
536	Application of kinomic array analysis to screen for altered kinases in atrial fibrillation remodeling. Heart Rhythm, 2018, 15, 1708-1716.	0.7	5
537	Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. Cardiovascular Research, 2021, 117, 1609-1611.	3.8	5
538	Electrophysiological engineering of heart-derived cells with calcium-dependent potassium channels improves cell therapy efficacy for cardioprotection. Nature Communications, 2021, 12, 4963.	12.8	5
539	Isolation and Study of Cardiac Nuclei from Canine Myocardium and Adult Ventricular Myocytes. Methods in Molecular Biology, 2015, 1234, 69-80.	0.9	5
540	Sinus Node Dysfunction and Sudden Cardiac Death Following Treatment with Encainide. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1607-1612.	1.2	4

#	Article	IF	CITATIONS
541	Are all sodium channel blockers created equal? Clinical-basic correlations based on observations in Brugada syndrome. Heart Rhythm, 2005, 2, 261-262.	0.7	4
542	Inward rectifier–funny current balance and spontaneous automaticity: Cautionary notes for biologic pacemaker development. Heart Rhythm, 2008, 5, 1318-1319.	0.7	4
543	Looking Into the Left Atrial Crystal Ball. Journal of the American College of Cardiology, 2010, 56, 579-581.	2.8	4
544	Canadian Journal of Cardiology: A Year of Change. Canadian Journal of Cardiology, 2012, 28, 5.	1.7	4
545	Combining distinctive and novel loci doubles BP reduction, reverses diastolic dysfunction and mitigates LV hypertrophy. Journal of Hypertension, 2013, 31, 927-935.	0.5	4
546	N-type calcium channel blockade: a new approach to preventing sudden cardiac death?. Cardiovascular Research, 2014, 104, 1-2.	3.8	4
547	Cardiac fibrillation—challenges and evolving solutions. Nature Reviews Cardiology, 2014, 11, 626-627.	13.7	4
548	Canadian Cardiovascular Society 2014 Algorithm for Anticoagulation Therapy in Atrial Fibrillation Debated. Canadian Journal of Cardiology, 2015, 31, 1-2.	1.7	4
549	T-tubular collagen: a new player in mechanosensing and disease?. Cardiovascular Research, 2017, 113, 839-840.	3.8	4
550	Postoperative Atrial Fibrillation After Noncardiac Surgery: Maybe Not So Benign After All. Canadian Journal of Cardiology, 2019, 35, 1423-1425.	1.7	4
551	Sex as a Key Variable in Predicting Cardiovascular Outcomes: Rapidly Evolving Knowledge but Much More Needed. Canadian Journal of Cardiology, 2020, 36, 1-3.	1.7	4
552	Ageing, comorbidities, and the complex determinants of atrial fibrillation in athletes. European Heart Journal, 2021, 42, 3526-3528.	2.2	4
553	Fish Oil Supplements May Increase the Risk for Atrial Fibrillation: What Does This Mean?. Circulation, 2021, 144, 1991-1994.	1.6	4
554	Antiarrhythmic drugs and strategies. , 2013, , 272-331.		4
555	Effect of frequent ventricular ectopy on myocardial infarct size in dogs. Cardiovascular Research, 1987, 21, 286-292.	3.8	3
556	Pulmonary vein cellular electrophysiology and atrial fibrillation: Does basic research help us understand clinical pulmonary-vein arrhythmogenesis?. Heart Rhythm, 2005, 2, 1346.	0.7	3
557	Preoperative Atrial Cardiomyocyte Ionic Currents and Postoperative AF: Important Insights Into What Is Not the Mechanism. Journal of Cardiovascular Electrophysiology, 2006, 17, 1239-1241.	1.7	3
558	The heart on a chip: The role of realistic mathematical models of cardiac electrical activity in understanding and treating cardiac arrhythmias. Heart Rhythm, 2007, 4, 779-780.	0.7	3

#	Article	IF	CITATIONS
559	Inefficacy of a Highly Selective Tâ€Type Calcium Channel Blocker in Preventing Atrial Fibrillation Related Remodeling. Journal of Cardiovascular Electrophysiology, 2014, 25, 531-536.	1.7	3
560	Pulmonary vein exit block despite recovery of entry conduction during redo-ablation for atrial fibrillation. Europace, 2015, 17, 752-752.	1.7	3
561	Editorial Commentary: Obesity, body composition and atrial fibrillation. Trends in Cardiovascular Medicine, 2020, 30, 212-214.	4.9	3
562	A computational model of pig ventricular cardiomyocyte electrophysiology and calcium handling: Translation from pig to human electrophysiology. PLoS Computational Biology, 2021, 17, e1009137.	3.2	3
563	Rhythm versus rate control for atrial fibrillation management: what recent randomized clinical trials allow us to affirm. Cmaj, 2003, 168, 572-3.	2.0	3
564	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. Circulation: Arrhythmia and Electrophysiology, 2022, , CIRCEP121010462.	4.8	3
565	Understanding, Predicting, Preventing, and Treating Ventricular Arrhythmias: Pushing Sudden Death Into Overtime. Canadian Journal of Cardiology, 2022, 38, 414-417.	1.7	3
566	Bevantolol Disposition in Patients with Hepatic Cirrhosis. Journal of Clinical Pharmacology, 1987, 27, 962-966.	2.0	2
567	Cost Evaluation of Rhythm Control Methods for Atrial Fibrillation: Evidence from CTAF. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 211-214.	1.0	2
568	Is Atrial Remodeling a Viable Target for Prevention of Atrial Fibrillation Recurrence?. Journal of Cardiovascular Electrophysiology, 2004, 15, 885-886.	1.7	2
569	Unique Quantitative Trait Loci in Synergy Permanently Improve Diastolic Dysfunction. Canadian Journal of Cardiology, 2013, 29, 1302-1309.	1.7	2
570	Increasing Appreciation for the Role of Single-Pill Combinations for the Prevention of Atherosclerotic Disease: A Pro-Polypill Polemic. Canadian Journal of Cardiology, 2014, 30, 517-519.	1.7	2
571	The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 973-981.	3.0	2
572	Direct Effects of Activation and Inhibition of the Coagulation System on the AtrialÂFibrillation Substrate. JACC Basic To Translational Science, 2016, 1, 340-343.	4.1	2
573	Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games. Canadian Journal of Cardiology, 2017, 33, 1517-1519.	1.7	2
574	Allele-Specific Gene Silencing. Circulation Research, 2017, 121, 480-482.	4.5	2
575	Consequences of Atrial or Ventricular Tachypacing on the Heat Shock Proteins (HSP) level of Expression and Phosphorylation. McGill Journal of Medicine, 2009, 12, 34.	0.1	2
576	Lidocaine — problems in understanding an antiarrhythmic drug. Trends in Pharmacological Sciences, 1982, 3, 297-300.	8.7	1

#	Article	IF	CITATIONS
577	Prevention of action potential duration accommodation to heart rate — A new antiarrhythmic mechanism?. Journal of the American College of Cardiology, 1991, 17, A360.	2.8	1
578	The Pathophysiology of Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 25-26.	1.0	1
579	Amiodarone Oral. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 262-269.	1.0	1
580	Azimilide. Drugs, 2000, 59, 279-278.	10.9	1
581	Sodium Channel Inactivation Abnormalities Associated with Heart Disease: Ionic Remodeling and Arrhythmogenic Channelopathies. Journal of Cardiovascular Electrophysiology, 2001, 12, 226-228.	1.7	1
582	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 162-165.	1.0	1
583	Specific potassium channel blockade for arrhythmia prevention in the ionically remodeled failing heart: Peril or panacea?. Heart Rhythm, 2005, 2, 739-740.	0.7	1
584	Teasing out circadian variability in heart rate turbulence: A new approach to detecting biorhythms underlying cardiac function. Heart Rhythm, 2007, 4, 301-303.	0.7	1
585	Repolarization indices or calcium-current recovery/repolarization balance: What determines torsadogenesis?. Heart Rhythm, 2008, 5, 280-281.	0.7	1
586	Complex fractionated atrial electrograms: Can they be made simple?. Heart Rhythm, 2008, 5, 855-856.	0.7	1
587	Evolving Developments in the Therapeutics of Atrial Fibrillation: Addressing an Unmet Need. Journal of Cardiovascular Pharmacology, 2008, 52, 1-3.	1.9	1
588	Cell calcium, repolarization changes, and spontaneous postshock fibrillation in failing hearts: Causes of refibrillation and electrical storm. Heart Rhythm, 2009, 6, 793-795.	0.7	1
589	Concealed Automaticity From an Island of Atrial Myocardium Post Cavotricuspid Ablation. Journal of Cardiovascular Electrophysiology, 2010, 21, 1408-1409.	1.7	1
590	Dormant pulmonary vein conduction unmasked by external electrical cardioversion. Heart Rhythm, 2010, 7, 1706-1707.	0.7	1
591	The Molecular Pathophysiology of Atrial Fibrillation. , 2014, , 449-458.		1
592	Reply. Journal of the American College of Cardiology, 2014, 63, 89-90.	2.8	1
593	Serum Uric Acid Concentration and Left Atrial Thrombus:ÂBiomarker, Pathophysiological Indicator, orÂlnnocentÂBystander?. Canadian Journal of Cardiology, 2014, 30, 1259-1261.	1.7	1
594	Modeling the Aging Heart: From Local Respiratory Defects to Global Rhythm Disturbances. Cell Metabolism, 2015, 21, 662-663.	16.2	1

#	Article	IF	CITATIONS
595	Innovative Therapeutics for Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2015, 66, 409-411.	1.9	1
596	Response by Lau et al to Letters Regarding Article, "Modifiable Risk Factors and Atrial Fibrillation― Circulation, 2018, 137, 1534-1535.	1.6	1
597	The Molecular Pathophysiology of Atrial Fibrillation. , 2018, , 396-408.		1
598	Catheter ablation of atrial fibrillation and outcomes in heart failure patients: seeking the treasure in the CASTLE. Cardiovascular Research, 2018, 114, e50-e52.	3.8	1
599	Computational models of the atrial fibrillation substrate: can they explain post-ablation recurrences and help to prevent them. Cardiovascular Research, 2019, 115, 1681-1683.	3.8	1
600	Clarity and controversy around rate control in AF, the orphan child in AF therapeutics. International Journal of Cardiology, 2019, 287, 189-194.	1.7	1
601	Natriuretic peptide receptors and atrial-selective fibrosis: potential role in atrial fibrillation. Cardiovascular Research, 2019, 115, 258-260.	3.8	1
602	Do Atrial Fibrillation–Promoting GeneÂVariants Act by Enhancing AtrialÂRemodeling?. JACC: Clinical Electrophysiology, 2020, 6, 1522-1524.	3.2	1
603	Risk Factors in Atrial Fibrillation: Appraisal of Atrial Fibrillation Risk Stratification. Cardiac Electrophysiology Clinics, 2021, 13, xix-xx.	1.7	1
604	Finding a new job: glutamate signaling acts in atrial cardiomyocytes. Cell Research, 2021, 31, 943-944.	12.0	1
605	Understanding the molecular events preceding and leading to atrial fibrillation. Heart Rhythm, 2021, 18, 2126-2127.	0.7	1
606	Cellular Electrophysiology and the Substrate for Atrial Fibrillation. , 2008, , 37-56.		1
607	Regulator of Câ€protein signalling 4 (RGS4) KO mice show increased susceptibility to atrial fibrillation. FASEB Journal, 2010, 24, 855.1.	0.5	1
608	Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation. , 2008, , 261-280.		1
609	Effects of encainide on the inducibility of ventricular arrhythmia in normal anesthetized dogs. Journal of Tongji Medical University, 1986, 6, 60-66.	0.1	0
610	Is Cardiac Migraine a Clinical Entity?. Clinical Nuclear Medicine, 1995, 20, 403-406.	1.3	0
611	Atrial Fibrillation: Experimental and Theoretical Developments. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 49-51.	1.0	0
612	The Pathophysiology of Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 85-87.	1.0	0

#	Article	IF	CITATIONS
613	Atrial Fibrillation: Experimental and Theoretical Developments. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 110-112.	1.0	0
614	The mechanisms of enhanced vulnerability to atrial fibrillation caused by atrial tachycardia-induced electrical remodeling: Insights from combined activation and refractoriness mapping. Journal of Electrocardiology, 1999, 32, 139.	0.9	0
615	Mechanisms of Antiarrhythmic Drug Actions. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 186-189.	1.0	0
616	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 263-267.	1.0	0
617	Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?. Cmaj, 2004, 171, 752-753.	2.0	0
618	Regional discrepancies in ionic currents and arrhythmia susceptibility: Clinical relevance. Heart Rhythm, 2005, 2, 177-178.	0.7	0
619	The beneficial effects of a novel specific chymase inhibitor, SUNC8257, on congestive heart failure-related atrial remodeling in dogs. Heart Rhythm, 2005, 2, S95-S96.	0.7	0
620	Ventricular tachyarrhythmia induction by strong cardiac shocks: Can understanding underlying mechanisms lead to improved prevention of defibrillator failure?. Heart Rhythm, 2006, 3, 596-597.	0.7	0
621	P3-7. Heart Rhythm, 2006, 3, S180.	0.7	0
622	Protein kinase C, connexin43, and ischemic preconditioning: Complex interactions of potential importance for controlling arrhythmias. Heart Rhythm, 2007, 4, 1194-1195.	0.7	0
623	To the Editor—Response. Heart Rhythm, 2008, 5, 636-637.	0.7	0
624	Experimental and Theoretical Insights into Fundamental Mechanisms of Antiarrhythmic Drug Actions on Atrial Fibrillation: Prospects for Improved Pharmacotherapy. , 2009, , 52-60.		0
625	Fast and furious: new ways to think about, study and treat cardiac arrhythmias. Journal of Physiology, 2009, 587, 1383-1384.	2.9	0
626	Frequency-domain versus time-domain analysis: Optimizing complex fractionated atrial electrogram identification for atrial fibrillation ablation. Heart Rhythm, 2009, 6, 1483-1484.	0.7	0
627	Erratum to "lon-channel mRNA-expression profiling: Insights into cardiac remodeling and arrhythmic substrates―[J. Mol. Cell. Cardiol. 48 (2010) 96–105]. Journal of Molecular and Cellular Cardiology, 2010, 48, 1335-1339.	1.9	0
628	Mechanisms of lethal arrhythmias due to acute myocardial ischemia: Regional factors and challenges in sudden death prevention. Heart Rhythm, 2010, 7, 387-388.	0.7	0
629	Reply to the Editor–Mechanoelectrical factors in M-cell debate. Heart Rhythm, 2011, 8, e2.	0.7	0
630	A Proud Tradition and a New Beginning With a Theme Issue on Atrial Fibrillation. Canadian Journal of Cardiology, 2011, 27, 5-6.	1.7	0

#	Article	IF	CITATIONS
631	A Focus on Hypertension: A Modest Condition of Enormous Significance. Canadian Journal of Cardiology, 2011, 27, 394-396.	1.7	0
632	Response to Letters Regarding Article, "Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training― Circulation, 2011, 124, .	1.6	0
633	Inflammation and Biomarkers in Vascular Disease: Emerging Insights and Opportunities. Canadian Journal of Cardiology, 2012, 28, 616-618.	1.7	0
634	Anticoagulation for Atrial Fibrillation: State of the Art and Recommendations for a Quickly Moving Target. Canadian Journal of Cardiology, 2013, 29, S1-S3.	1.7	0
635	Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation. , 2013, , 333-352.		0
636	Rebuttal from Eduard Guasch and Stanley Nattel. Journal of Physiology, 2013, 591, 4947-4947.	2.9	0
637	A Look Into the Future of Cardiology: Perspectives From the Montreal Heart Institute. Canadian Journal of Cardiology, 2014, 30, S399-S400.	1.7	0
638	Atrial Ectopic Activity in Long-Standing Persistent Atrial Fibrillation: An Unanticipated Potentially Important Role?. Canadian Journal of Cardiology, 2014, 30, 1496-1497.	1.7	0
639	Results-Based Accountability for Cardiovascular Epidemiology Research by the National Heart, Lung, and Blood Institute. Circulation, 2015, 132, 1949-1952.	1.6	0
640	Cardiac Potassium Channel Disorders: From Basics to Clinics. Cardiac Electrophysiology Clinics, 2016, 8, xv-xvi.	1.7	0
641	Basic Electrophysiology. Cardiovascular Medicine, 2017, , 1-13.	0.0	0
642	Prof Niels Voigt talks to Prof Stanley Nattel about advances in atrial fibrillation research and career insights. Cardiovascular Research, 2018, 114, e65-e65.	3.8	0
643	Notes From Cardiology Clinic: Medicine Is More Than Just Pills, Procedures, and Devices. Canadian Journal of Cardiology, 2019, 35, 1263-1264.	1.7	0
644	Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA2DS2-VASc and Support for CHADS-65. Canadian Journal of Cardiology, 2019, 35, 547-549.	1.7	0
645	The Canadian Journal of Cardiology: Open and Growing. Canadian Journal of Cardiology, 2019, 35, 133-137.	1.7	0
646	Reply. Journal of the American College of Cardiology, 2020, 76, 2179-2180.	2.8	0
647	In Memoriam—Martial G. Bourassa (1931-2020). Canadian Journal of Cardiology, 2020, 36, 1562-1563.	1.7	0
648	A Focus on COVID-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients. Canadian Journal of Cardiology, 2020, 36, 787-788.	1.7	0

#	Article	IF	CITATIONS
649	Cardiac Na/Ca Exchange Suppression: A Lateâ€Breaking Knockout Story Showing That There Is No Free Lunch. Journal of the American Heart Association, 2021, 10, e022512.	3.7	0
650	Oita International Electrocardiology Symposium 2000 "Electrophysiology and Management of Lethal Arrhythmias in the New Millennium: From Genes to Bedside― Japanese Journal of Electrocardiology, 2000, 20, 6-10.	0.0	0
651	The Use of Cardiovascular Drugs: Pharmacological Principles. , 2007, , 35-39.		0
652	Familial Idiopathic Ventricular Fibrillation Linked to Chromosome 7q36 Harboring DPP6. Journal of Arrhythmia, 2011, 27, OP59_4.	1.2	0
653	Cholinergic and Constitutive Regulation of Atrial Potassium Channel. , 2014, , 383-391.		0
654	Digital Technologies: Revolutionizing Cardiovascular Medicine and Reshaping the World. Canadian Journal of Cardiology, 2022, 38, 142-144.	1.7	0
655	Atrial fibrillation in heart failure: A practical approach for the clinician. Canadian Journal of Cardiology, 2022, , .	1.7	0
656	Atrial fibrillation: basic and clinical research at the Montreal Heart Institute. Canadian Journal of Cardiology, 2005, 21, 1091-6.	1.7	0
657	PO-616-07 THE ROLE OF CELLULAR SENESCENCE IN ATRIAL FIBRILLATION. Heart Rhythm, 2022, 19, S113-S114.	0.7	0